References
- American Diabetes Association. Data and Statistics about Diabetes. Available at: http://professional.diabetes.org/admin/UserFiles/0%20-%20Sean/Documents/Fast_Facts_3-2015.pdf. Accessed September 25, 2015
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care 2015;38:140-9
- Wright A, Burden ACF, Paisey RB, et al.; for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study. Diabetes Care 2002;25:330-6
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12
- Wu N, Aagren M, Boulanger L, et al. Assessing achievement and maintenance of glycemic control by patients initiating basal insulin. Curr Med Res Opin 2012;28:1647-56
- Brunton S, Blonde L, Chava P, et al. Characteristics of patients with type 2 diabetes mellitus (T2DM) on basal insulin who do not achieve glycemic goals. Oral presentation 112. 50th European Association for the Study of Diabetes Annual Meeting, 16–19 September 2014, Vienna, Austria. Available at http://www.easdvirtualmeeting.org/resources/19732. Accessed on September 25, 2015
- Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin 2011;27:887-95
- Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther 2014;5:225-42
- Baser O, Tangirala K, Wei W, Xie, L. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res 2013;5:497-505
- Wang L, Wei, W, Miao R, et al. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMC Open 2013;3:e002348
- Thayer S, Wei W, Buysman E, et al. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. Adv Ther 2013;30:1128-40
- Davis KM, Tangirala M, Meyers JL, Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy Curr Med Res Opin 2013;29:1083-91
- Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231-8
- Bonafede M, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010;4:147-56
- Wei W, Pan C, Xie L, Baser O. Real-world insulin treatment persistence among patients with type 2 diabetes. Endocrine Practice 2014;20:52-61
- Perez-Nieves M, Jiang D, Eby E. Incidence, prevalence, and trend analysis of the use of insulin delivery systems in the United States (2005 to 2011). Curr Med Res Opin 2015;31:(5):891-9
- US Census Bureau. Regions and Division. Available at http://www.census.gov/econ/census/help/geography/regions_and_divisions.html. Accessed on January 5, 2016
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
- Imbens G. The role of the propensity score in estimating dose–response functions. Biometrika 2000;87:706-10